Cryptome Discovers Novel Compounds to Treat Cancer
This class of compound has already been filed for anticoagulant properties. Cryptome will be investigating these molecules to select one or more lead candidates and then will proceed to determine efficacy in relevant disease animal models. Further details of the clinical potential in cancer and the molecular basis of these compounds will be released as the results of this work become available.
Cryptome's Chief Scientific Officer, Dr Vic Ilag noted, "The invention once again covers a broad and novel class of compounds and not a single molecule. Our team were able to produce this result in less than a year from the time we initiated our cancer drug discovery programme. This is much quicker than the 3 years or more for conventional discovery programmes starting from target identification".
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.